Search Results | MSF Science Portal

Journal Article

|

Research

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, et al.

2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article

|

Research

Jelsma J, Maclean E, Hughes J, Tinise X, Darder M

2005-07-01 • AIDS Care

The health authorities have recently accepted the routine provision of highly active antiretroviral therapy to persons living with AIDS in South Africa. There is a need to investigate th...

Journal Article

|

Short Report

Cox HS, Hughes J, Black JM, Nicol MP

2018-03-13 • Lancet Infectious Diseases

Treatment for drug-resistant tuberculosis is largely delivered through standardised, empirical combination regimens in low-resource, high-burden settings. However, individualised treatme...

Journal Article

|

Letter

Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V, et al.

2015-12-01 • European Respiratory Journal

Journal Article

|

Research

Cox HS, Hughes J, Daniels J, Azevedo VD, McDermid C, et al.

2014-04-01 • International Journal of Tuberculosis and Lung Disease

SETTING: Khayelitsha, South Africa, a peri-urban township with high burdens of tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and human immunodeficiency virus (HIV) infection.

Journal Article

|

Research

Daniels J, Khogali MA, Mohr E, Cox V, Moyo S, et al.

2015-11-10 • PLOS One

SETTING
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.

OBJECTIVE
To describe time to antiretroviral trea...

Journal Article

|

Research

Ndjeka N, Campbell JR, Meintjes GA, Maartens G, Schaaf HS, et al.

2022-05-02 • Lancet Infectious Diseases

BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...

Journal Article

|

Letter

Cox HS, Ford NP, Hughes J, Goemaere E

2013-01-01 • Lancet Infectious Diseases

Journal Article

|

Short Report

Reuter A, Hughes J, Furin J

2019-09-14 • Lancet

Children bear a substantial burden of suffering when it comes to tuberculosis. Ironically, they are often left out of the scientific and public health advances that have led to important...

Journal Article

|

Research

Ismail N, Omar SV, Moultrie H, Bhyat Z, Conradie F, et al.

2021-11-12 • Lancet Infectious Diseases

BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...

Journal Article

|

Commentary

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S, et al.

2020-11-01 • International Journal of Tuberculosis and Lung Disease

Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...

Journal Article

|

Research

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, et al.

2018-09-08 • Lancet

BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...

Journal Article

|

Research

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison CCH, Hughes J, et al.

2018-02-13 • Lancet Infectious Diseases

BACKGROUND
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...

Journal Article

|

Research

Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M, et al.

2020-10-01 • International Journal of Tuberculosis and Lung Disease

Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...

Journal Article

|

Letter

Cox V, Wilkinson LS, Grimsrud A, Hughes J, Reuter A, et al.

2020-04-02 • International Journal of Tuberculosis and Lung Disease

Journal Article

|

Research

Ndjeka N, Schnippel K, Master I, Meintjes GA, Maartens G, et al.

2018-10-25 • European Respiratory Journal

Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...

Journal Article

|

Research

Mohr E, Daniels J, Beko B, Isaakidis P, Cox V, et al.

2017-05-18 • PLOS One

BACKGROUND
Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administer...

Journal Article

|

Letter

Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V, et al.

2015-04-02 • European Respiratory Journal

Journal Article

|

Commentary

Cox HS, Hughes J, Ford NP, London L

2012-03-01 • Lancet Infectious Diseases

Journal Article

|

Research

Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, et al.

2015-07-19 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.

OBJECTIVE
To descri...

Science Portal

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART

Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?

Linezolid in drug-resistant tuberculosis: haste makes waste

Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa

Time to ART initiation among patients treated for rifampin-resistant tuberculosis in Khayelitsha, South Africa: Impact on mortality and treatment success

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa a retrospective cohort study

Linezolid for multidrug-resistant tuberculosis

Challenges and controversies in childhood tuberculosis

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?

Critical changes to services for TB patients during the COVID-19 pandemic

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting

Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients

MDR tuberculosis and non-compliance with therapy

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis